Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Dottino, JA, Hasselblad, V, Secord, AA, Myers, ER, Chino, J, and Havrilesky, LJ. "Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis." Obstetrics and Gynecology 128, no. 4 (October 2016): 747-753.

Full Text

Jr, MRJ, Armstrong, DK, Alvarez, RD, Bakkum-Gamez, JN, Behbakht, K, Chen, L-M, Copeland, L, Crispens, MA, DeRosa, M, Dorigo, O, Gershenson, DM, Gray, HJ, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Martin, L, Matulonis, UA, O'Malley, DM, Penson, RT, Percac-Lima, S, Pineda, M, Plaxe, SC, Powell, MA, Ratner, E, Remmenga, SW, Rose, PG, Sabbatini, P, Santoso, JT, Werner, TL, Burns, J, and Hughes, M. "Ovarian Cancer, Version 1.2016." Journal of the National Comprehensive Cancer Network 14, no. 9 (September 2016): 1134-1163.

Full Text

Morgan, RJ, Armstrong, DK, Alvarez, RD, Bakkum-Gamez, JN, Behbakht, K, Chen, L-M, Copeland, L, Crispens, MA, DeRosa, M, Dorigo, O, Gershenson, DM, Gray, HJ, Hakam, A, Havrilesky, LJ, Johnston, C, Lele, S, Martin, L, Matulonis, UA, O'Malley, DM, Penson, RT, Percac-Lima, S, Pineda, M, Plaxe, SC, Powell, MA, Ratner, E, Remmenga, SW, Rose, PG, Sabbatini, P, Santoso, JT, Werner, TL, Burns, J, and Hughes, M. "Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : Jnccn 14, no. 9 (September 2016): 1134-1163.

Full Text

Ehrisman, J, Secord, AA, Berchuck, A, Lee, PS, Di Santo, N, Lopez-Acevedo, M, Broadwater, G, Valea, FA, and Havrilesky, LJ. "Performance of sentinel lymph node biopsy in high-risk endometrial cancer." Gynecologic oncology reports 17 (August 2016): 69-71.

Full Text

Davidson, BA, Foote, J, Clark, LH, Broadwater, G, Ehrisman, J, Gehrig, P, Graybill, W, Alvarez Secord, A, and Havrilesky, LJ. "Tumor grade and chemotherapy response in endometrioid endometrial cancer." Gynecologic oncology reports 17 (August 2016): 3-6.

Full Text

Wallbillich, JJ, Forde, B, Havrilesky, LJ, and Cohn, DE. "A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy." Gynecologic Oncology 142, no. 1 (July 2016): 144-149.

Full Text

Phippen, NT, Havrilesky, LJ, Barnett, JC, Hamilton, CA, Stany, MP, and Lowery, WJ. "Does Routine Posttreatment PET/CT Add Value to the Care of Women With Locally Advanced Cervical Cancer?." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 26, no. 5 (June 2016): 944-950.

Full Text

Secord, AA, and Havrilesky, LJ. "Is Intraperitoneal Chemotherapy Dead?." Obstetrics and Gynecology 127, no. 6 (June 2016): 983-984.

Full Text

Hong, JC, Foote, J, Havrilesky, LJ, Gaillard, S, and Chino, JP. "Chemotherapy and radiotherapy in early stage uterine papillary serous and clear-cell carcinoma: A National Cancer Data Base study." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 3, 2016 - June 7, 2016.: AMER SOC CLINICAL ONCOLOGY, May 20, 2016.

Scholars@Duke

Foote, J, Liang, M, Secord, AA, Cohn, DE, and Havrilesky, LJ. "Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum sensitive ovarian cancer." May 20, 2016.

Full Text

Pages